Research & Development News Channel

Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants

Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

Their new study, published online on July 1, 2021 in Cell Reports Medicine, shows that both CD4+ "helper" T cells and CD8+ "killer" T cells can still recognize mutated forms of the virus.

COVID-19 vaccine reduces severity, length, viral load for those who still get infected

Individuals who contract COVID-19 even after vaccination are likely to have a lower viral load, experience a shorter infection time and have milder symptoms than people who are unvaccinated, according to research that includes data from ongoing University of Arizona Health Sciences studies.

COVID-19 vaccines have prevented 7.2 million infections and 27,000 deaths in England alone

Latest modelling analysis from Public Health England (PHE) and the University of Cambridge’s MRC Biostatistics Unit suggests that the coronavirus (COVID-19) vaccination programme has so far prevented an estimated 7.2 million infections and 27,000 deaths in England alone.

Virus that causes COVID-19 can find alternate route to infect cells

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. All current COVID-19 vaccines and antibody-based therapeutics were designed to disrupt this route into cells, which requires a receptor called ACE2.

Drug doubles down on bone cancer, metastasis

Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis.

COVID-19 dual-antibody therapies effective against variants in animal study

COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise.

COVID-19 vaccines pre-prepared in syringes can be safely transported

One of the main reasons for the hold-ups in the mass vaccination campaigns against COVID-19 are the precautions that must be taken regarding the handling of the vaccines and their administration. They have to be transported under very specific conditions and the syringes used for their administration must be prepared at the same vaccination site.

Research & Development News

Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants

COVID-19 vaccine reduces severity, length, viral load for those who still get infected

COVID-19 vaccines have prevented 7.2 million infections and 27,000 deaths in England alone

Virus that causes COVID-19 can find alternate route to infect cells

Drug doubles down on bone cancer, metastasis

COVID-19 dual-antibody therapies effective against variants in animal study

COVID-19 vaccines pre-prepared in syringes can be safely transported

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs